Journal article
Predictors of Driving Cessation in Dementia: Baseline Characteristics and Trajectories of Disease Progression
MH Connors, D Ames, M Woodward, H Brodaty
Alzheimer Disease and Associated Disorders | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
Abstract
A diagnosis of dementia implies the eventual need to relinquish driving. This is associated with significant morbidity and anticipating when it will need to occur can be important for planning. Patients, however, vary in the course of their disease. We sought to identify predictors of driving cessation in patients with dementia, including both baseline characteristics and changes in cognition and function over time as indicators of disease trajectory. A total of 779 patients with dementia were recruited from 9 memory clinics around Australia. Patients and their carers reported their driving status and completed measures of dementia severity, cognition, function, neuropsychiatric symptoms, an..
View full abstractGrants
Funding Acknowledgements
[ "The Dementia Centre for Research Collaboration is funded by the National Health and Medical Research Council. Data collection was funded in part by Janssen-Cilag Pty Limited. Janssen-Cilag had no input into the design, execution, analysis, interpretation, or writing of this study.", "In the last 3 years, D.A. has received grants/funds for clinical trials from Eli Lilly and PranaBio, honoraria from Lundbeck, Pfizer, and Servier. He has been a consultant for PranaBio's data safety monitoring board. He has received royalties for edited books from Cambridge University Press and Hodder. He has attended advisory board meetings of Eli Lilly. M.W. has worked on drug trials funded by pharmaceutical companies including AbbiVie, Astra Zeneca, AZ therapies, Biogen, Buck, Eisai, Janssen, Lilly, Lundbeck, Merck/MSD, Novartis, Pfizer, Roche, Servier, Takeda, Tau Rx, vTv Therapeutics and Zinfandel. He has received honoraria for consultancy or presentations at meetings organized by CogRx, Lundbeck, Merk Sharp & Dohme, Novartis, and Nutricia. H.B. has worked on drug trials for patients with mild cognitive impairment and Alzheimer disease sponsored by Sanofi-Aventis, Servier and Tau Therapeutics. He has also been a consultant and/or advisory board member for Eli Lilly and Nutricia. M.H.C. declares no conflicts of interest." ]